An FDA analysis has identified important safety information for patients using Wegovy. The weight-loss medication carries a significantly elevated risk of non-arteritic anterior ischemic optic neuropathy (NAION) compared to Ozempic due to higher prescribed doses, affecting approximately 8.7 per million prescriptions.
Key considerations for patients include: first, the higher dosing required for weight management (versus diabetes treatment) appears responsible for the increased risk; second, vision loss from NAION typically develops rapidly within hours to days; and third, recognizing warning signs is critical. Sudden vision changes, including blurred vision, vision loss in one eye, or eye pain, warrant immediate medical evaluation.
Patients currently taking Wegovy should not discontinue use without consulting their healthcare provider, but should maintain awareness of these symptoms. Medical professionals prescribing Wegovy should discuss this risk with patients and ensure they understand when to seek emergency care. Read the full article on GMJ Newsroom.
Was this article helpful?
